Payment overview · 2025
General Payments
$815.25
33 reported records · 13 companies
Healthcare provider profile · identity verified
Macy Williamson, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · LUVERNE, AL · NPI 1740848639
Verified facts
What the public records show
CMS Open Payments records show Macy Williamson, CRNP received $815.25 in general payments during 2025 across 33 reported records.
Incyte Corporation accounted for 36.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Eliquis by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Incyte Corporation | Unresolved — no canonical attribution shown | $298.72 | 36.6% | 12 | 2025 |
| SEAGEN INC. | Unresolved — no canonical attribution shown | $77.99 | 9.6% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $68.28 | 8.4% | 3 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $63.79 | 7.8% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $63.15 | 7.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $56.51 | 6.9% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $54.30 | 6.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.09 | 4.5% | 2 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $23.72 | 2.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.20 | 2.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.69 | 2.4% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $15.16 | 1.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.65 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $638.26 | 31 |
| Education | $176.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $122.68 | 7 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $77.04 | 4 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $68.28 | 3 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $68.28 | 3 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $63.79 | 2 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $63.15 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $56.51 | 3 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $54.30 | 2 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $38.64 | 2 | 2025 |
Source payment records
|
|||||
| PEMAZYRE Normalized: pemazyre |
Drug | Incyte Corporation | $38.40 | 2 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Biological, Drug | ABBVIE INC., Genentech USA, Inc. | $37.36 | 2 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.09 | 2 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.09 | 2 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.09 | 2 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $23.72 | 1 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
103 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
88 | 21 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 188 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 159 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 42 |
| Omeprazole | Omeprazole | 120 | 38 |
| Farxiga | Dapagliflozin Propanediol | 103 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 30 |
| Potassium Chloride | Potassium Chloride | 95 | 31 |
| Eliquis | Apixaban | 88 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 25 |
| Metformin Hcl Er | Metformin Hcl | 74 | 30 |
| Amlodipine Besylate | Amlodipine Besylate | 73 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 69 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 31 |
| Carvedilol | Carvedilol | 67 | 22 |
| Furosemide | Furosemide | 67 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 23 |
| Jardiance | Empagliflozin | 64 | 16 |
| Famotidine | Famotidine | 58 | 18 |
| Lisinopril | Lisinopril | 58 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 56 | 20 |
| Trazodone Hcl | Trazodone Hcl | 56 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | 20 |
| Losartan Potassium | Losartan Potassium | 54 | 22 |
| Ramipril | Ramipril | 54 | 24 |
| Sertraline Hcl | Sertraline Hcl | 49 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 11 |
| Spironolactone | Spironolactone | 47 | 13 |
| Linzess | Linaclotide | 46 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 20 |
| Bumetanide | Bumetanide | 43 | 12 |
| Montelukast Sodium | Montelukast Sodium | 41 | 13 |
| Alendronate Sodium | Alendronate Sodium | 40 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 11 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 12 |
| Ozempic | Semaglutide | 35 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Valsartan | Valsartan | 28 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Mupirocin | Mupirocin | 25 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Cefdinir | Cefdinir | 22 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 19 |
| Meloxicam | Meloxicam | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Simvastatin | Simvastatin | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | 11 |
| Digoxin | Digoxin | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 12 | 12 |
| Sucralfate | Sucralfate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $815.25 · 33 records | Incyte Corporation | BESREMI, DARZALEX, EVENITY, IMFINZI, JAKAFI, LIBTAYO, Lenvima, MONJUVI, MONOFERRIC, Nubeqa, OPDIVO, PEMAZYRE, Stivarga, TALVEY, VENCLEXTA, Vitrakvi, ZYNYZ | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error